Zacks Research Has Bearish Estimate for Bruker Q3 Earnings

Bruker Co. (NASDAQ:BRKR) – Zacks Research reduced their Q3 2025 earnings per share (EPS) estimates for Bruker in a note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $0.72 per share for the quarter, down from their prior forecast of $0.94. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.96 EPS.

BRKR has been the topic of a number of other research reports. TD Cowen cut their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Citigroup decreased their price objective on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Barclays cut their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and an average target price of $79.36.

Bruker Price Performance

Bruker stock opened at $57.95 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. Bruker has a 52-week low of $48.07 and a 52-week high of $94.86. The firm has a market cap of $8.79 billion, a PE ratio of 27.91, a price-to-earnings-growth ratio of 3.92 and a beta of 1.20. The company’s 50 day moving average is $60.82 and its two-hundred day moving average is $64.20.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. During the same quarter in the prior year, the firm posted $0.74 EPS. Bruker’s quarterly revenue was up 16.4% compared to the same quarter last year.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently modified their holdings of BRKR. FMR LLC raised its stake in shares of Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after buying an additional 2,521,904 shares in the last quarter. State Street Corp grew its holdings in Bruker by 9.6% during the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock worth $250,501,000 after acquiring an additional 318,808 shares during the period. RTW Investments LP raised its position in Bruker by 1.1% in the third quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock worth $240,406,000 after acquiring an additional 37,024 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Bruker by 10.8% in the third quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after acquiring an additional 193,580 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Bruker by 127.8% during the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock worth $88,666,000 after purchasing an additional 779,549 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the purchase, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 28.30% of the stock is owned by company insiders.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be paid a dividend of $0.05 per share. The ex-dividend date is Monday, December 2nd. This represents a $0.20 annualized dividend and a yield of 0.35%. Bruker’s dividend payout ratio is currently 9.62%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.